RecruitingNCT04914026
MicroRNA as Markers in Testicular Cancer
MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours
Sponsor
Haukeland University Hospital
Enrollment
350 participants
Start Date
Dec 31, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
The main objective of this study is establish the performance of miR371 in management of testicular cancer
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 70 Years
Inclusion Criteria4
- Patients with suspected testicular cancer, referred to orchiectomy.
- Patients diagnosed with testicular germ cell cancer.
- Age 18-70 years of age.
- Must be able receive information and to consent.
Exclusion Criteria2
- Other prior or concomitant malignancy (other than testicular cancer).
- Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.
Interventions
OTHERBiomarker analysis
Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04914026
Related Trials
Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity
NCT074635081 location
THERApy De-escalation for TESTicular Cancer
NCT063097451 location
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
NCT061335431 location